Proliferating cell nuclear antigen (PCNA) is necessary for DNA synthesis and is an accessory protein for DNA polymerase alpha, which is elevated during the G1/S phase of the cell cycle. PCNA forms a ring around a portion of DNA, serving to anchor the various DNA replication and repair proteins and to regulate proliferation throughout the cell cycle. In staining applications, the PCNA antibody exhibits nuclear staining (1,2). PCNA is overexpressed in many cancer types, and overexpression is correlated with cancer virulence with studies showing that PCNA is directly related to the degree of tumor differentiation, stage of cancer and the prognosis of cancer. PCNA-targeting peptides were shown to inhibit the growth or to induce apoptosis in neuroblastoma, prostate cancer, breast cancer, bladder cancer, and multiple myeloma (3,4).



FORMAT ConcentratePrediluteUltraLine
VOLUME 0.1 ml1.0 ml6.0 ml
SOURCE Mouse Monoclonal
SPECIES REACTIVITY Human; others not tested
ISOTYPE IgG2a/kappa
POSITIVE CONTROL Breast cancer and prostate cancer

1. Guo JL, et al. Evaluation of Clinical Significance of Endoglin Expression During Breast Cancer and Its Correlation with ER and PCNA. Eur Rev Med Pharmacol Sci. 2017 Dec; 21(23):5402-7.
2. Bologna-Molina R, et al. Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumor. Med Oral Patol Oral Cir Bucal. 2013 Mar; 18(2):e174–9.
3. Shemesh A, et al. NKp44-Derived Peptide Binds Proliferating Cell Nuclear Antigen and Mediates Tumor Cell Death. Front Immunol. 2018; 9:1114.
4. Zhao H, et al. Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer. PLoS One. 2012; 7(1):e29416.
5. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
6. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

VP Echelon Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare’s antibodies by Ventana Medical Systems, Inc. Biocare and Ventana are not affiliated, associated or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.


There are no reviews yet.

Be the first to review “PCNA [PC10]”

Your email address will not be published. Required fields are marked *